Patents by Inventor Augusto C. Ochoa
Augusto C. Ochoa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9752145Abstract: Provided are compositions and methods of use thereof that modulate C/EBP homologous stress-related protein (Chop) activity in Myeloid-derived Suppressor Cells (MDSCs). Chop is a key point in the response of MDSCs to tumor-generated stress factors. In turn, the MDSCs release cytokines and other factors that function as immune suppressors, thereby allowing the tumors to thrive and expand. By inhibiting the level of Chop activity, the immunosuppressive function of MDSCs is disrupted. It has also been unexpectedly found that there is a concomitant increase in the ability of MDSCs to act as antigen-presenting and cytokine producing cells so as to act in increasing the efficacy of anti-tumor immune-based therapies.Type: GrantFiled: March 16, 2015Date of Patent: September 5, 2017Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Paulo Cesar Rodriguez, Augusto C. Ochoa
-
Publication number: 20170002351Abstract: Provided are compositions and methods of use thereof that modulate C/EBP homologous stress-related protein (Chop) activity in Myeloid-derived Suppressor Cells (MDSCs). Chop is a key point in the response of MDSCs to tumor-generated stress factors. In turn, the MDSCs release cytokines and other factors that function as immune suppressors, thereby allowing the tumors to thrive and expand. By inhibiting the level of Chop activity, the immunosuppressive function of MDSCs is disrupted. It has also been unexpectedly found that there is a concomitant increase in the ability of MDSCs to act as antigen-presenting and cytokine producing cells so as to act in increasing the efficacy of anti-tumor immune-based therapies.Type: ApplicationFiled: March 16, 2015Publication date: January 5, 2017Inventors: PAULO CESAR RODRIGUEZ, AUGUSTO C. OCHOA
-
Publication number: 20040057926Abstract: The present invention provides methods and compositions for modulating an immune response by controlling the level of arginase available to a cell, tissue or system. An immune response can be enhanced or depressed by altering the amount of arginine available to a cell, tissue or system through the manipulation of localized or systemic arginine levels using substances which provide arginine to the body and enzymes which break down arginine, such as arginase and nitric oxide synthase. Increasing or decreasing an immune response according to the present invention provides therapeutic treatments for a variety of conditions and diseases. The present invention also provides clinical methods and kits which can measure the strength or resistance to an immune response in a cell, tissue or system based upon the amount of available arginine and enzymes which break down arginine.Type: ApplicationFiled: March 12, 2003Publication date: March 25, 2004Applicant: LSU Medical CenterInventors: Augusto C. Ochoa, Juan B. Ochoa, Mircea Popescu, Arnold H. Zea, Paulo C. Rodriguez
-
Publication number: 20030021838Abstract: A vaccine comprising a liposome preparation including at least one B-cell malignancy-associated antigen, IL-2, alone or in combination with at least one other cytokine, and at least one type of lipid molecule, is useful in a method of inducing humoral and cellular immune responses against malignant B-cells in a mammal.Type: ApplicationFiled: November 5, 2001Publication date: January 30, 2003Inventors: Mircea C. Popescu, Larry Kwak, Augusto C. Ochoa, Larry Boni
-
Patent number: 6312718Abstract: A vaccine comprising a liposome preparation including at least one B-cell malignancy-associated antigen, IL-2, alone or in combination with at least one other cytokine, and at least one type of lipid molecule, is useful in a method of inducing humoral and cellular immune responses against malignant B-cells in a mammal.Type: GrantFiled: October 27, 1998Date of Patent: November 6, 2001Assignee: Biomira USA, Inc.Inventors: Mircea C. Popescu, Larry Kwak, Augusto C. Ochoa, Larry Boni
-
Patent number: 5965366Abstract: Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM).Type: GrantFiled: June 23, 1997Date of Patent: October 12, 1999Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Biormia USA Inc.Inventors: Augusto C. Ochoa, Howard A. Young, Dan L. Longo, Paritosh Ghosh
-
Patent number: 5889143Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.Type: GrantFiled: September 16, 1996Date of Patent: March 30, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Augusto C. Ochoa, Dan L. Longo, Paritosh Ghosh, Howard A. Young
-
Patent number: 5773006Abstract: The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.Type: GrantFiled: April 7, 1995Date of Patent: June 30, 1998Assignee: Regents of the University of MinnesotaInventors: Peter M. Anderson, Arnold S. Leonard, Augusto C. Ochoa, Cynthia Loeffler
-
Patent number: 5658744Abstract: Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM).Type: GrantFiled: July 22, 1994Date of Patent: August 19, 1997Assignees: The United States of America as represented by the Department of Health and Human Services, Biomira USA Inc.Inventors: Augusto C. Ochoa, Howard A. Young, Dan L. Longo, Paritosh Ghosh, Richard Robb, Mary Neville
-
Patent number: 5650152Abstract: The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.Type: GrantFiled: December 10, 1993Date of Patent: July 22, 1997Assignee: Regents of the University of MinnesotaInventors: Peter M. Anderson, Arnold S. Leonard, Augusto C. Ochoa, Cynthia Loeffler
-
Patent number: 5583002Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels and T-lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, or a protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.Type: GrantFiled: December 11, 1992Date of Patent: December 10, 1996Assignees: Regents of the University of Minnesota, The United States of America as represented by the Department of Health and Human ServicesInventors: Augusto C. Ochoa, Hiromoto Mizuguchi, John J. O'Shea, Dan L. Longo, Cynthia M. Loeffler
-
Patent number: 5556763Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.Type: GrantFiled: March 17, 1993Date of Patent: September 17, 1996Assignee: United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Augusto C. Ochoa, Dan L. Longo, Paritosh Ghosh, Howard A. Young
-
Patent number: 5443983Abstract: In accordance with the present invention, a method of culturing lymphocytes is disclosed in which the lymphocytes are cultured in the presence of interleukin-2 (IL-2) and an antibody to a lymphocyte surface receptor, preferably an antibody to a lymphocyte T3 surface receptor. Preferably, the antibody is monoclonal. Cells cultured with anti-CD3 maintain their LAK activity as they increase in number. The cells can also be cultured in the presence of an additional lymphokine to obtain additional LAK activity.Methods of medical treatment are also disclosed in which cells cultured in accordance with the culturing methods of the present invention are introduced into the individual to be treated.Type: GrantFiled: March 21, 1988Date of Patent: August 22, 1995Assignee: Regents of the University of MinnesotaInventors: Augusto C. Ochoa, Fritz H. Bach, Barbara Alter, Paul Sondel
-
Patent number: 5409698Abstract: The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.Type: GrantFiled: October 28, 1992Date of Patent: April 25, 1995Assignee: The Regents of The University of MinnesotaInventors: Peter M. Anderson, Arnold S. Leonard, Augusto C. Ochoa, Cynthia Loeffler
-
Patent number: 5316763Abstract: The present invention is directed to a method of increasing the in vivo immune response of lymphocytes by stimulating the lymphocytes in vitro in the presence of an anti-CD3 monoclonal antibody for less than about 24 hours to form stimulated lymphocytes; infusing the stimulated lymphocytes into a tumor-bearing mammal; and administering IL-2 to the mammal. As a result of this method, the anti-CD3 stimulated lymphocytes display enhanced immunotherapeutic, e.g., cytotoxicity or lymphokine production, in vivo as represented by a decrease in the number of tumors by at least about 20%.Type: GrantFiled: July 10, 1992Date of Patent: May 31, 1994Assignees: The United States of America as represented by the Department of Health and Human Services, Regents of the University of MinnesotaInventors: Augusto C. Ochoa, Cynthia Loeffler, Walter Urba, Dan L. Longo
-
Patent number: 5296353Abstract: A method of determining the level of immunosuppression in a mammal involves determining the level of expression of at least one selected TCR subunit protein, or protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in healthy individuals. The method is useful to identify patients having T lymphocytes capable of activation for autologous adoptive immunotherapy and for identifying agents which cause or reverse immunosuppression.Type: GrantFiled: April 6, 1992Date of Patent: March 22, 1994Assignees: The United States of America as represented by the Department of Health and Human Services, Regents of the University of MinnesotaInventors: Augusto C. Ochoa, Hiromoto Mizoguchi, John J. O'Shea, Dan L. Longo, Cynthia M. Loeffler